Vericel’s Strongest Quarter Yet: MACI Scale, BARDA Infusion, and the Agili-C Non-Event

Q1 revenue +30%, guidance raised $10M, and a $197M BARDA contract begins to pay.

VCEL · Earnings Call · 2026-05-07

A Stronger Starting Point

Vericel entered 2026 with a record Q1: total revenue hit $68.4 million, up 30% y/y and well above guidance. Total revenue surged to $68 million, while gross margin expanded 300bps to 72% and adjusted EBITDA more than tripled to $9.6 million. “Total revenue increased 30% to $68.4 million, which was significantly above our guidance range for the quarter” — Joseph Mara, Chief Financial Officer · 2026-05-07 — a clear sign that demand is running ahead of plan. For the full year, management lifted revenue guidance by $10 million, to $326–336 million, while reaffirming margin targets. The company also generated over $15 million of free cash flow, its third consecutive quarter above $12 million, and ended the period with $211 million in cash. The acceleration is broad-based: MACI’s trailing four-quarter growth reached 23%, and Burn Care grew 90% year-over-year. The Q1 outperformance, which CFO Joe Mara described as “in the $4–5 million range versus guidance,” was partly absorbed into the guide, with the rest coming from the newly secured BARDA contract.

Sales-Force Scaling Drives MACI

MACI revenue grew 22% to $56.4 million, with the newly expanded sales force showing early muscle. The company added territories and realigned its team in Q1, and results have been encouraging. As Nick Colangelo put it: “we're capitalizing on our larger MACI sales force, which meaningfully increases overall reach across our MACI target surgeons and provides an opportunity to continue to drive growth in new MACI surgeons as well as <keyword id="05b260777c">deeper penetration within MACI surgeon practices</keyword>” — Dominick C. Colangelo, President and Chief Executive Officer · 2026-05-07. That penetration theme was already building in prior calls — on the February call, Nick noted, “the dynamics that we see once the surgeons are trained regardless of which bucket they come out of sort of hold true” — Dominick C. Colangelo, President and Chief Executive Officer · 2026-02-26, underscoring that the model is repeatable. Biopsies per surgeon accelerated, and pull-through to implants improved, especially in the new territories, with management explicitly crediting the larger sales force for driving higher conversion rates across the board.

MACI Arthro: Data and Traction

MACI Arthro continues to be a growth engine, with over 1,000 surgeons trained and a new data set suggesting faster recovery. Early case series point to reduced postoperative pain, better range of motion, and earlier full weight-bearing — outcomes that were accepted for publication. This trajectory was anticipated in the November call, where Joe Mara commented, “we're seeing exactly what we wanted to see as we kind of march through the year” — Joseph Mara, Chief Financial Officer · 2025-11-06. The company also secured FDA approval for MACI commercial manufacturing at its new facility, which enables both U.S. capacity expansion and a path to a U.K. launch in 2027. These milestones de-risk the growth story and extend the runway.

Burn Care: The BARDA Windfall

Burn Care revenue jumped 90% to $12 million, driven by strong Epicel performance and a rebound from the COVID-era trough. The bigger headline is the BARDA contract, valued at up to $197 million, with a base award of $35 million. Nick highlighted its significance:

We're very pleased to work with BARDA to support U.S. national preparedness for potential mass casualty events and to drive further development of NexoBrid.
Dominick C. Colangelo, President and Chief Executive Officer · 2026-05-07

Initial procurement revenue of $5–6 million is expected in H2, with the full contract laying out a 10-year framework around stockpiling, R&D, and potential room-temperature formulations. This adds a non-commercial revenue stream and validates NexoBrid’s strategic role beyond its small current sales (~$1.1 million in Q1).

Agili-C: A Non-Threat

Competitive concerns around Agili C remain muted. Management continues to dismiss overlap, noting the product targets older osteoarthritic patients, not the young, active MACI population. As Nick put it: “we actually don't think there's a lot of overlap” — Dominick C. Colangelo, President and Chief Executive Officer · 2026-05-07 — and he added that Agili-C is contraindicated in patella defects, which remain MACI’s strongest segment. With prior-authorization rates in the mid-90s range and no meaningful competitive disruption, the outlook appears secure. The market continues to treat MACI as the clear leader in restorative cartilage repair, and the company is now leveraging that position via BARDA award to diversify its funding sources.

Financial Outlook & the Road Ahead

The company expects ~20% revenue growth for the full year, with MACI growing in the high-teens and Burn Care benefiting from both core growth and BARDA procurement. Margins are projected to improve further — gross margin guidance of ~75% and adjusted EBITDA margin of ~27% for the year, up from 2025 levels. With free cash flow now consistently positive and a strong cash balance, Vericel has the resources to fund its commercial expansion, the Ankle trial, and international expansion. As Nick remarked: “we’re really well positioned to continue to deliver what is a very unique combination of sustained high revenue growth, profitability and cash generation.” The combination of a larger sales force, MACI Arthro data, and a BARDA cash stream positions Vericel for sustained growth, and the stock’s recent +27% uptick over three months suggests the market is starting to recognize the inflection.